Supplemental material
Leukemia & Lymphoma
Volume 55, 2014 - Issue 3
Open access
1,168
Views
14
CrossRef citations to date
0
Altmetric
Research Article
Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
Brian S. ChoiCompassionate Cancer Care Medical Group,
Riverside, CA, USACorrespondence[email protected]
, Gabriela P. BorsaruSpitalul Clinic Coltea,
Bucharest, Romania
, Gianluca BallinariHelsinn Healthcare SA,
Pambio-Noranco, Switzerland
, Daniel VoisinHelsinn Healthcare SA,
Pambio-Noranco, Switzerland
& Nicola Di RenzoP.O. Vito Fazzi,
Lecce, Italy
Pages 544-550
|
Received 25 Feb 2013, Accepted 05 Jun 2013, Published online: 24 Jul 2013
Related Research Data
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer
Source:
Future Medicine Ltd
Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting
Source:
Springer Science and Business Media LLC
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
Source:
UK : Oxford University Press
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update
Source:
Springer Science and Business Media LLC
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Source:
American Society of Clinical Oncology (ASCO)
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy
Source:
Springer Science and Business Media LLC
Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients
Source:
Elsevier BV
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Source:
American Society of Clinical Oncology (ASCO)
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Source:
American Society of Clinical Oncology (ASCO)
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial
Source:
Springer Nature
Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting
Source:
Elsevier BV
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall
Source:
Springer Science and Business Media LLC
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.